Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > REGULATORY
REGULATORY
- Cancer Policy Promotion Council Submits New 5-Year Plan to Health Minister Komiyama
March 5, 2012
- Revised Ordinance Banning “Dispensing Point” Services Announced in Official Gazette
March 5, 2012
- 11 APIs/28 Products to Receive Premiums for New Pediatric, Orphan Indications
March 5, 2012
- PAFSC’s 2nd Committee on Drugs Recommends Approval for Pfizer Japan’s ALK Inhibitor Xalkori
March 1, 2012
- MHLW Study Group Approves Outline of “Post-5-Year Plan” for Promoting Clinical Trials
March 1, 2012
- PAFSC’s 2nd Committee on Drugs Recommends Orphan Drug Designation for 4 Products
February 29, 2012
- MHLW Conducts Hearing on Distribution Improvement with Drug Manufacturers
February 28, 2012
- Ikoma City Introduces Pharmacy Certification System to Promote Use of Generics
February 28, 2012
- Non-partisan Study Group Holds Hearings on Problem of Essential But Unprofitable Drugs
February 28, 2012
- Next 5-Year Strategy Calls for Boost to Japanese“Rising Sun”Seed Development
February 27, 2012
- PAFSC’s First Committee on Drugs Recommends Approval for Eli Lilly’s Once-Weekly GLP-1 Receptor Agonist
February 27, 2012
- National, Rosai Hospitals Hold 1st Meeting Aimed at Joint Purchasing in July
February 27, 2012
- Welfare Offices to Dispatch “Advisors” to Visit Welfare Recipients and Encourage Generic Drug Use
February 27, 2012
- Health Insurance Law Revision Study Group Formed, Calling for Legal Presence for Regulatory Guidance
February 24, 2012
- Measures to Eliminate Drug Lag “Fully Implemented”: GRU Report
February 24, 2012
- Novartis Pharma’s Pasireotide Designated as Orphan Drug for Cushing’s Disease
February 24, 2012
- PAFSC Committee on New Drugs Approves Orphan Drug Designation for 3 Products
February 24, 2012
- DPJ’s PAL Subcommittee to Form Opinion on Amendment of PAL in March
February 23, 2012
- MEXT to Make Drug Education Compulsory at Junior High Schools from FY2012
February 23, 2012
- MHLW to Promote Multinational Clinical Trials in East Asia to Reduce Drug Lag
February 23, 2012
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…